Underestimation of urinary biomarker-to-creatinine ratio resulting from age-related gain in muscle mass in rats.

Tonomura Y, Morikawa Y, Takagi S, Torii M, Matsubara M.
Journal   Toxicology
Analytes Measured   Albumin , Clusterin , HAVCR1 KIM-1
Matrix Tested   Urine
Year   2012
Page Numbers  
Application   Toxicology
Recent efforts have been made to identify useful urinary biomarkers of nephrotoxicity. Furthermore, the application of urine to the other toxicities as new biomarker source has been recently expanded. Meanwhile, correction of urinary biomarker concentrations according to fluctuations in urine flow rate is required for adequate interpretation of the alteration. The urinary biomarker-to-creatinine ratio (UBCR) is widely used because of the convenience, while the urinary biomarker-excretion rate is regarded as the gold standard corrective method. Because creatinine is a catabolite in energy production in muscles, we hypothesized that altered muscle mass could affect creatinine kinetics, ultimately affecting UBCR. However, no study has examined this hypothesis. In this study, we examined the influence of muscle mass gain on UBCR, using male Sprague-Dawley rats during the growth phase, 6-12-week old. Both plasma creatinine and excretion of urinary creatinine (Ucr excretion) showed increases with muscle mass gain in rats, in which the alterations of UBCR were lowered. The renal mRNA level of the organic cation transporter-2 (Oct2), a creatinine transporter, showed an age-related increase, whereas the mRNA level of multidrug and toxin extrusions-1 (Mate1) remained constant. Multiple regression analysis showed that the increase in creatinine clearance highly contributed to the age-related increase in Ucr excretion compared to the mRNA levels of Oct2 and Mate1. This suggested that the age-related increase in Ucr excretion may be attributable to the increased transglomerular passage of creatinine. In conclusion, the results suggest that muscle mass gain can affect creatinine kinetics, leading to underestimation of UBCR. Therefore, it is important to understand the characteristics of the corrective method when using urinary biomarker, the failure of which can result in an incorrect diagnosis.

View Publications

Related Products

R-PLEX Human Albumin Antibody Set
Albumin | Human
R-PLEX Rat HAVCR1/KIM-1 Antibody Set
KIM-1 | Rat
R-PLEX Human HAVCR1/KIM-1 Antibody Set
KIM-1 | Human
R-PLEX Human Clusterin Antibody Set
Clusterin | Human
Kidney Injury Panel 3 Human Kit
α-GST, Calbindin, Clusterin, KIM-1, Osteoactivin, TFF3, VEGF-A | Human
Kidney Injury Panel 5 Human Kit
Albumin, B2M, Cystatin C, EGF, NGAL/LCN2, Osteopontin, Uromodulin | Human
Rat Clusterin Kit
Clusterin | Rat
Human KIM-1 Kit
KIM-1 | Human
KIM-1 | Rat
Kidney Injury Panel 1 Rat Kit
Albumin, KIM-1, NGAL/LCN2, Osteopontin | Rat
Browse Our Products

By Analytes
By Applications
Customer Service/Orders

Scientific/Technical Support

Instrument Support

Company Headquarters